No Data
No Data
The disclosure of the annual report of the subsidiary Gidao Biotech was delayed until June, and there may be competition issues in the industry
Gelonghui, April 27 | Since the acquisition of Jingchuan Diagnostics, a company listed on the Shanghai Main Board in 2020, the two have continued to conflict as parent companies and subsidiaries for several years. On April 26, the subsidiary Jingchuan Diagnosis issued the “Notice of Resolutions of the 10th Meeting of the 3rd Board of Directors”. The announcement shows that on April 24, 2024, 5 directors of Jingchuan Diagnosis voted on 12 proposals, including the “Proposal on the Company's 2023 Annual Report and Summary” and the “Proposal on the Company's 2023 Capital Utilization Special Report”.
The lawsuit extends to the rival base of the industry, and the dispute between Egg Biotech and the shareholders of the subsidiary intensifies
① Recently, the small and medium shareholders of Jingchuan Diagnostics were sued by the small and medium shareholders of Jingchuan Diagnostics, and this is only one part of the fight between the two sides; ② Jingchuan Diagnostics made an exclusive response to the Financial Federation reporter saying that several lawsuits have only been filed in August of last year, and that management and employees expect the dispute to be resolved as soon as possible; ③ the industry believes that the intention to continue to acquire Gidao Biotech is not strong, or that it has caused a “soft confrontation” with Jingchuan Diagnosis.
Is Weakness In Getein Biotech, Inc (SHSE:603387) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
With its stock down 20% over the past three months, it is easy to disregard Getein Biotech (SHSE:603387). But if you pay close attention, you might gather that its strong financials could mean that
Getein Biotech, Inc (SHSE:603387) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
The Getein Biotech, Inc (SHSE:603387) share price has fared very poorly over the last month, falling by a substantial 25%. Instead of being rewarded, shareholders who have already held through the
Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 8.1% Price Drop
Key Insights Getein Biotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 25 s
Basic Egg Biology (603387): Multi-production line layout and platform-based construction first take shape
Key investment points: Deeply involved in the industry for more than 20 years, speeding up the layout of multiple product lines, and platform-based construction taking shape. At the beginning of its establishment, the company continued to develop in vitro diagnosis, and gradually built a POCT line based on chemiluminescence, coagulation, and flow
No Data